This segment focuses on the research, development, and commercialization of therapies for rare genetic disorders that cause obesity. The primary focus is on the melanocortin-4 receptor (MC4R) pathway. Research and development activities include clinical trials for setmelanotide in various genetic obesity disorders, including POMC, LEPR, and Bardet-Biedl syndrome. The company utilizes advanced biotechnology and small molecule drug development methodologies. The lead product, IMCIVREE (setmelanotide), is designed to address the underlying genetic causes of obesity, improving patient outcomes by reducing weight and addressing related health complications. Market positioning is centered on addressing unmet needs in rare disease markets, with a competitive advantage in targeted therapies. Future opportunities include expanding the label for IMCIVREE and developing new therapies for other rare genetic disorders. Regulatory and clinical aspects involve obtaining FDA and EMA approvals and conducting post-market studies. Partnerships and collaborations are essential for clinical trials and market access.